InfinityQS Demonstrates Quality’s Impact on the Vaccine Manufacturing Chain in New eBook
News Oct 08, 2014
InfinityQS International, Inc. has published an eBook, “Transforming the Vaccine Manufacturing Chain: How Pharmaceutical Companies Can Ensure Quality and Accelerate Time to Market.” This new eBook discusses why quality must play a more prominent role in vaccine production and demonstrates how technology can help overcome the quality challenges of the increasingly complex, global pharmaceutical supply chain. The eBook is available for download at www.infinityqs.com/Vaccine_eBookPR.
Within this eBook, quality managers in the life sciences space will discover how a Manufacturing Intelligence system, or quality hub, can strengthen the entire supply chain by turning the following challenges into opportunities:
• Data Proliferation: The intricacies of the pharmaceutical supply chain, rapid advances in medical science, and increasingly sophisticated vaccine formulations create vast amounts of data. A quality hub helps better manage big data by enabling real-time data collection and breaking down silos of disparate information. As a result, operators can proactively monitor quality and take action before issues occur, while management can leverage these data to identify areas for improvement.
• The Global Supply Chain: Many manufacturers rely on multiple locations and suppliers across the globe to produce a single vaccine. With a cloud-based quality hub, manufacturers can attain a complete view of quality data across the entire supply chain from anywhere at any time. This insight ensures the quality of the final product, expedites time to market and supports the organization’s entire global strategy.
• Regulatory Requirements: Increasingly complex regulatory requirements, like 21 CFR Part 11, force manufacturers to not only implement additional processes to maintain compliance, but also to validate these processes. A quality hub provides quick access to meaningful data that can be easily configured into reports to ensure compliance throughout the product’s entire lifecycle.
Michael Lyle, president and CEO, InfinityQS, said, “With more vaccines on the market and a growing worldwide demand, manufacturers are under a great deal of pressure to generate enough vaccines that comply with the industry’s stringent regulations. Today’s manufacturers must place a greater emphasis on their quality programs and consider the benefits of a Manufacturing Intelligence system in order to quickly and efficiently produce safe, high-quality vaccines that keep people healthy and save lives.”
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Antigen Study Shows Promise for a Respiratory Syncytial Virus VaccineNews
Medical researchers have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 50 years, without success. New findings however, point to a promising route for designing an effective vaccine. Researchers determined the atomic structure of RSV G (major viral surface protein) and identified two sites on it that are targeted by protective antibodies effective against a broad range of RSV strains.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018